We designed and implemented a new mitoxantronebased high-dose chemotherapy regimen to minimize pulmonary injury (seen in carmustine-based regimens) in patients with breast cancer. One hundred and ninetyone breast cancer patients (99 stage II/IIIA; 27 stage IIIB; 65 stage IV responsive to conventional-dose chemotherapy) were treated with high-dose chemotherapy (CTM) delivered over 4 days (cyclophosphamide (6 g/m 2 ), thiotepa (600 mg/m 2 ), and mitoxantrone (24-60 mg/m 2 )) followed by autologous hematopoietic stem cell rescue. Stage II/III patients received chest wall radiation and tamoxifen (if hormone-receptor positive) after CTM. The 5-year event-free survival (EFS) for stage II/IIIA patients with 10 or more involved axillary lymph nodes (n = 80) was 62 ؎ 12%. Hormone receptor-positive patients with 10 or more nodes did significantly better than negative patients. The EFS for stage IIIB patients at 5 years was 44 ؎ 19%; for stage IV patients at 5 years was 17 ؎ 10%. Stage IV patients achieving complete response in viscera and/or soft tissue prior to CTM did significantly better than those achieving a partial response. There were six (3%) treatment-related deaths including two due to diffuse alveolar hemorrhage. There were no episodes of delayed interstitial pneumonitis. There were six severe cardiac events in 91 patients (6.6%) but none after instituting mitoxantrone dose-adjustment in the final 100 patients. We conclude that CTM is associated with a low treatment-related mortality and little pulmonary toxicity. CTM produces excellent outcomes in stage II/IIIA patients with 10 or more involved axillary lymph nodes. Bone Marrow Transplantation (2000) 26, 257-268. Keywords: breast cancer; high-dose chemotherapy; mitoxantrone; stem cells
and 10 or more involved axillary lymph nodes (у10 nodes). [6] [7] [8] Although the role of HDCT in patients with recurrent or metastatic breast cancer has been controversial, 9 -12 a recent prospective, randomized trial demonstrated a remission duration and survival advantage for HDCT compared to conventional-dose chemotherapy in patients with untreated advanced breast cancer. 13 The optimal HDCT regimen for breast cancer remains to be defined. Carmustine-based HDCT regimens are complicated by interstitial pneumonitis and the hemolytic-uremic syndrome. 6, [14] [15] [16] We sought to develop an effective HDCT regimen for breast cancer without significant pulmonary toxicity. In this report we describe the results of a phase I-II trial combining high-dose cyclophosphamide, thiotepa and mitoxantrone (CTM) with hematopoietic stem cell rescue for poor prognosis breast cancer.
Materials and methods

Patient eligibility
Women with breast cancer were enrolled and treated on this study from 1 May 1990 to 1 August 1996. All patients had a histologic diagnosis of breast cancer. Patients under age 65 were eligible for enrollment if evaluation of their general health and organ function was adequate for HDCT as follows: (1) Karnofsky performance status у80%; (2) cardiac ejection fraction, as determined by radionuclide study or echocardiogram, у50% at rest or у40% at rest if the ejection fraction increased to у50% with exercise; (3) pulmonary diffusing capacity of carbon monoxide у50%; (4) serum creatinine р2 mg/dl; (5) total bilirubin р2 mg/dl; (6) morphologically normal bilateral bone marrow aspirate and biopsy within 1 month of bone marrow harvest or collection of peripheral blood stem cells (PSC). Patients were not eligible if they had a prior history of congestive heart failure or myocardial infarction or documented central nervous system metastases. This treatment protocol and consent form were approved by our Institutional Review Boards in accordance with the Helsinki Declaration. All patients gave written, informed consent for protocol treatment.
Cancer-related eligibility criteria were as follows. All staging was performed according to the American Joint Committee on Cancer. 17 Stage IV patients with measurable disease were eligible for HDCT only if they had a complete (CR) or partial response (PR) to conventional-dose chemotherapy. 18 Patients with bone metastases were required to demonstrate normalization of hypercalcemia, resolution of bone pain, and a reduction or stabilization in the size and/or number of bony lesions on radionuclide bone scan following conventional-dose chemotherapy. Patients with boneonly metastases were included. Easily assessable bone lesions were needle biopsied prior to chemotherapy. Stage IV patients rendered free of measurable disease by surgical biopsy were eligible without documentation of chemotherapy sensitivity and categorized as CR. Stage IIIB (inflammatory or non-inflammatory) patients were eligible if they had an objective response (CR or PR) to neo-adjuvant (pre-mastectomy) induction chemotherapy. Patients determined to be stage IIIB following mastectomy without previous chemotherapy were eligible. Stage II/IIIA patients were eligible for HDCT if they had: (1) у10 axillary lymph nodes involved at diagnosis; or (2) T 3 primary tumor with у4 involved axillary lymph nodes; or (3) T 1 or T 2 primary tumor with four or more involved axillary lymph nodes and all of the following features: estrogen and progesterone-receptor negativity, S-phase Ͼ5%, and aneuploidy.
Treatment
Induction chemotherapy: Conventional-dose induction chemotherapy was administered to all patients prior to HDCT. to five cycles of induction chemotherapy. The number of treatment cycles was not strictly defined so as to allow time to acquire insurance authorization for HDCT. Stage IIIB generally received two to four pre-mastectomy cycles of chemotherapy followed by one to two more cycles prior to HDCT. Stage IV patients received one to 13 cycles of induction chemotherapy in order to establish an objective response.
Intensification treatment: HDCT was delivered intravenously on days −6 to −3. The doses of drugs were: cyclophosphamide 1. . Starting in early 1995, mitoxantrone doses were administered over 21 h to approximate a continuous infusion in an effort to reduce the risk of cardiac toxicity. Patients whose actual body weight was 101-150% of their predicted ideal body weight had their body surface area (BSA) calculated using a corrected weight (ideal weight plus (0.25) (actual weight − ideal weight), all weights in kg). Patients whose actual weight was Ͼ150% of ideal had their BSA calculated using a corrected weight which was 112.5% of ideal weight.
If 8 /kg). The marrow buffy coat was separated from the marrow suspension by centrifugation (COBE 2991 or COBE Spectra, Denver, CO, USA) and cryopreserved as previously described. 19 On day zero of HDCT, the bone marrow was rapidly thawed in a 37°C water bath at the patient's bedside and infused through a central venous catheter following 25 g of intravenous mannitol as renal failure prophylaxis.
One hundred and thirty-three patients had stem cells collected from their peripheral blood in lieu of pelvic bone marrow. Patients received growth factor alone (G-CSF, 10 g/kg/day subcutaneous) or induction chemotherapy plus growth factor to mobilize peripheral blood stem cells. 20 G-CSF was begun 5 days before the anticipated first collection of PSC. Twelve to 18 liters of blood were processed via leukopheresis (COBE Spectra) to collect 250 cc of buffy coat, which was then cryopreserved. PSC were thawed and infused on day zero of HDCT. Three of these patients initially received only PSC but later also received backup BM because of poor engraftment. Eleven other patients with poor PSC collections (Ͻ50 × 10 4 CFU-GM/kg and Ͻ3 × 10 6 CD34 + cells/kg) also had pelvic bone marrow collected and infused with their PSC. Patients received daily G-CSF (5 g/kg) subcutaneously beginning on the day of PSC infusion or on day +6 post-PSC infusion until the absolute granulocyte count was Ͼ1500/l on 2 consecutive days or Ͼ5000/l on 1 day.
Supportive care
Patients received leukopoor and irradiated platelet and red blood cell transfusions when the morning platelet count was Ͻ15 000/l and hematocrit Ͻ25%, respectively. Cytomegalovirus (CMV)-seronegative patients received only CMV-negative blood products. Patients were started on vancomycin (or cefazolin), ceftazidime, and amphotericin B (0.3 mg/kg/day) when the neutrophil count fell to Ͻ500/l following HDCT. Acyclovir (2 mg/kg i.v. every 12 h) was started day −2 and later switched to 200 mg p.o. three times a day for 3-12 months post HDCT. Trimethoprim/sulfamethoxazole, one double strength tablet p.o. twice a day for 2 days a week, was given as Pneumocystis carinii prophylaxis up to three months post HDCT (or until the CD4 lymphocyte count was у200/l).
Post-HDCT evaluations
Stage IV patients were evaluated by history, physical examination, radionuclide bone scan, biopsies and CT/MRI scans (where appropriate) 3 months after HDCT. Thereafter, patients were seen every 6 months at the transplant center and re-evaluated when appropriate. Stage II/III patients were seen every 6 months post HDCT. A mammogram and chest X ray were performed yearly. During phase I, patients had a repeat cardiac ejection fraction determined approximately 1 year after HDCT.
Response criteria and definitions
Standard response and progression criteria were used as previously defined. 18 In addition, partial response ‡ (PR ‡ ) was defined as the complete disappearance of all measurable and detectable non-bony lesions (for at least four weeks) with residual radionuclide bone scan abnormalities in sites of prior metastatic disease. 21 Treatment-related mortality (TRM) was any death related to HDCT but not due to breast cancer. Cardiac toxicities were defined as follows: (1) severe cardiac toxicity, an absolute left ventricular ejection fraction (LVEF) Ͻ0.3, clinical congestive heart failure (CHF), or other life-threatening cardiac event; (2) moderate cardiac toxicity, a decrease in LVEF of у0.15 compared to baseline or LVEF 0.3-0.45 based on radionuclide cardiography. 22 A lifetime cumulative doxorubicin equivalent dose (⌺ Doxo Eq) was calculated for each patient
. 23 
Statistical evaluations
Differences between toxicity parameters at the various mitoxantrone doses and differences between engraftment endpoints based on the source of stem cells (BM, PSC, or both) were analyzed via one-way ANOVA with Scheffe post-hoc pair-wise comparisons. Differences between preand post-HDCT LVEF were analyzed via the paired-sample Student's t-test. The Kaplan-Meier estimates for overall (OS), event-free (EFS), disease-free (DFS) and progression-free (PFS) survivals were determined from the date of stem cell infusion. For purposes of EFS analysis, Bone Marrow Transplantation events are defined as non-breast cancer death, relapse of breast cancer, or first progression of breast cancer. To calculate DFS, relapses of breast cancer were events and treatment-related deaths were censored. To calculate PFS, relapses or first progression of breast cancer were events and treatment-related deaths were censored. Survival data are presented as probabilities Ϯ 95% confidence intervals. Comparisons between survival curves were made via the Mantel-Cox log rank test. Survival data were analyzed as of 15 March 1999.
Results
Patient characteristics
One hundred and ninety-one patients were treated ( Table  1 ). The median age of the entire group was 46 years (24-66). The median follow-up of the entire group is 51 months (11-90). One hundred and twenty of 175 patients (69%) were known to be ER and/or PgR positive at diagnosis. In stage II/IIIA patients with у10 nodes, the median number of involved lymph nodes was 14.5 . The median number of chemotherapy cycles administered to stage II/IIIA patients pre-HDCT was three (2-12) and to stage IIIB patients pre-HDCT was four (2) (3) (4) (5) (6) (7) (8) . Stage IV patients received a median of two courses (1-5) of conventional chemotherapy to document responsive disease. Stage IV patients received a median of three cycles (1-13) of the chemotherapy to which they responded immediately prior to HDCT.
Outcomes for primary breast cancer
Outcomes for the 126 patients with primary breast cancer by stage and number of involved axillary lymph nodes are shown in Table 2 . In stage II/IIIA patients with у10 nodes, the 5-year EFS was 62 Ϯ 12% ( Figure 1a ) and the 5-year DFS was 65 Ϯ 12%. In this group there were 29 relapses, four beyond 5 years post HDCT. The median EFS was 81 months (the median OS has not been reached). Of these 29 relapses, three were local-regional and 26 were distant (five, isolated central nervous system; nine, liver; three, bone only; three, distant lymph nodes only; two, pleura/lung; one, contralateral breast; three, other). The distant metastasis-free survival at 5 years was 68 Ϯ 12%. Univariate analysis was performed to determine factors predictive of DFS and OS. Factors examined were: hormone receptor-positive vs negative, stage II vs IIIA, primary tumor size р2.0 cm vs Ͼ2.0 cm, and 10-19 involved lymph nodes vs у20. Only hormone receptor status was predictive ( Figure 2 ). Hormone receptor-positive patients had a better 5-year DFS (69 Ϯ 14%, P = 0.12) and OS (78 Ϯ 12%, P = 0.007) than hormone receptor-negative patients (56 Ϯ 22% and 54 Ϯ 21%, respectively). The relative risk of relapse (RR = 1.8, 95% CI 0.8-4.0) trended higher in the hormone receptor-negative patients and the relative risk of death (RR = 3.2, 95% CI 1.4-7.3) was significantly higher in hormone receptor-negative patients (P Ͻ 0.03).
In 16 stage II/IIIA patients with 4-9 involved axillary lymph nodes, the 5-year EFS was 64 Ϯ 26% (Table 2 ). In b P р 0.05 compared to stage IV (PR); c P = 0.008 compared to stage IV (PR). TRM = treatment-related mortality; DFS = disease-free survival; EFS = event-free survival; OS = overall survival; LN = axillary lymph nodes; CR = complete response; PR ‡ = complete response in soft tissue and viscera, but persistent abnormal bone scintigraphy.
this group there were six relapses (all distant, none in the central nervous system). Although the 5-year OS (87 Ϯ 17%) appeared better in this group than in those stage II/IIIA patients with у10 nodes, this difference did not reach statistical significance.
The 5-year EFS for 27 stage IIIB breast cancer patients was 44 Ϯ 19% (Table 2, Figure 1a ). Fifteen patients relapsed (one local-regional, 14 distant), two isolated in the central nervous system. The distant metastasis-free survival for stage IIIB patients at 5 years was 51 Ϯ 19%. The median EFS and OS for these patients was 31 months and 56 months, respectively.
Outcomes for advanced breast cancer
The outcomes for 65 patients with stage IV breast cancer are shown in Table 2 . The 5-year EFS for this group was 17 Ϯ 10% (Figure 1a) . The median EFS and OS for stage IV patients as a whole were 13 and 28 months, respectively (Figure 1a and 1b) . , and PR), disease status following HDCT, sites of metastatic disease (bone only, soft tissue only, visceral dominant), and single metastatic organ vs multiple metastatic organ sites. Of these, patients entering HDCT in CR/PR ‡ was predictive of a better 5-year EFS (21 Ϯ 15% vs 11 Ϯ 11%; P = 0.026) and OS (40 Ϯ 17% vs 14 Ϯ 13%; P = 0.008) compared to patients entering HDCT in PR (Table 2, Figure 3 ). Achieving CR prior to HDCT (P = 0.05), PR ‡ prior to HDCT (P Ͻ 0.02), or CR following HDCT (P Ͻ 0.02) was predictive of better OS compared to patients entering HDCT in PR or never achieving CR following HDCT (Table 2) . No other factors were predictive of outcome. , respectively, received BM. Engraftment was faster with PSC. Comparing PSC to BM, the days post-infusion to achieve WBC Ͼ1000/l were 10.4 and 15.5 (P Ͻ 0.001), to achieve platelet transfusion independence were 11.9 and 23.6 (P Ͻ 0.01), and to achieve red blood cell transfusion independence were 12.5 and 22.3 (P Ͻ 0.01), respectively. Patients receiving PSC needed fewer platelet transfusions (5.1 vs 14.1, P Ͻ 0.001) and fewer red blood cell transfusions (4.7 vs 9.1, P Ͻ 0.001), respectively. The total hospital days for PSC patients was shorter (24.3 vs 33.3, P Ͻ 0.001). PSC patients required less intravenous narcotics (8.0 vs 13.5 days; P Ͻ 0.001) and less total parenteral nutrition (12.5 vs 23.0 days; P Ͻ 0.001) than BM patients. 
Treatment-related toxicities
There were six treatment-related deaths (Table 3) . Causes of death were: diffuse alveolar hemorrhage (two); acute myocardial infarction 1 month after hospital discharge (one); hepatic failure following reactivation of hepatitis B (one); CHF (one); and CHF and pulmonary hemorrhage without platelet engraftment 6 months after HDCT (one). One adjuvant patient died suddenly (in complete remission) of electrolyte imbalance from a weight reduction diet more than 1 year post HDCT. This is not counted as a treatmentrelated death. Grade 3 or 4 extramedullary toxicities were uncommon (Table 3) . There was one case of hemolyticuremic syndrome which occurred in a stage IIIB patient 1 year after HDCT coincident with a new diagnosis of systemic scleroderma. This patient ultimately died of sclerodermal renal crisis in complete remission of her breast cancer. There were seven cases of CMV infection (pneumonia, four; gastroenteritis, two; viremia, one), all of which responded to gancyclovir and intravenous gammaglobulin. There were nine documented episodes of Herpes zoster 3-25 months after HDCT (none occurring during acyclovir prophylaxis). There was no difference between the various mitoxantrone levels in grade 3 or greater hepatic, gastrointestinal, pulmonary, or cutaneous toxicity, as well as time to hospital discharge or total days of parenteral nutrition and narcotic drips. The development of cardiac events, related to prior total anthracycline exposure, prevented the determination of the MTD of mitoxantrone. The mean ⌺ Doxo Eq (including the HDCT mitoxantrone) for all patients was 332 Ϯ 28 mg/m 2 . For 97 patients with paired pre-and post-HDCT LVEF, these values were 62.9 ± 6.9%, and 56.6 ± 9.4%, respectively (P Ͻ 0.0001). Six patients (3%) experienced severe cardiac toxicity (Table 3 ). An interim analysis of cardiac toxicity was performed when 91 patients had been treated. Four of 24 patients (17%) with a ⌺ Doxo Eq у400 mg/m 2 experienced severe cardiac toxicity compared to two of 67 patients (3%) with Ͻ400mg/m 2 (P Ͻ 0.05). As a result, subsequent patients on study received a mitoxantrone dose adjustment: for stage II/IIIA patients, 40 mg/m 2 was administered; for stage IIIB/IV patients, 40, 50 or 60 mg/m 2 was administered using the largest of these doses which kept the ⌺ Doxo Eq Ͻ400 mg/m 2 . Since mitoxantrone doseadjustment there have been no further severe cardiac events. Thirteen of 97 patients (13%) with paired pre-and post-HDCT LVEF had moderate cardiac toxicity; only three of these patients had a LVEF Ͻ 0.45 and none had CHF.
After 135 patients had been treated, the daily mitoxantrone administration time was changed from 1 hour to 21 h. Of 97 patients with paired pre-HDCT and post-HDCT LVEF, 75 received the 1-h mitoxantrone bolus and 22 the 21-h mitoxantrone infusion. The ⌺ Doxo Eq for the two groups was similar and there was no significant difference in the pre-HDCT or post-HDCT LVEF between these two groups (Table 4) . Likewise, there was no difference in the ⌺ Doxo Eq, pre-HDCT LVEF, or post-HDCT LVEF comparing bolus mitoxantrone to infusion mitoxantrone in the subgroups of patients receiving 40 mg/m 2 or 60 mg/m 2 mitoxantrone (Table 4) . There were two cases of diffuse alveolar hemorrhage syndrome. Both died despite treatment with high-dose corticosteroids. 24, 25 There were no cases of late interstitial pneumonitis after hospital discharge. All stage II/III patients received chest wall radiation therapy. In general, radiation was well tolerated with no cases of radiation pneumonitis and only minimal, non-life-threatening depression in blood counts. Two patients developed second neoplasms. One was localized mycosis fungoides which occurred at 22 months post HDCT. This patient had thymic radiation as a child and had previously developed thyroid cancer before she developed breast cancer. The other patient developed anal cancer 9 months post HDCT. There were no cases of myelodysplasia or acute myelogenous leukemia.
Discussion
The outcomes of stage II/IIIA patients with у10 nodes receiving conventional-dose adjuvant chemotherapy have been uniformly poor. The 5-year DFS ranges from 17 to 56% (weighted average 38%). [6] [7] [8] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Four trials have been published using HDCT/PSC as treatment for stage II and/or IIIA patients with у10 nodes. [6] [7] [8] 39, 40 The 5-year DFS with HDCT is substantially better (range 50-64%, weighted average 58%) compared to patients receiving conventionaldose adjuvant chemotherapy. Our series of 80 stage II/IIIA patients with у10 nodes had a 5-year EFS of 62 Ϯ 12% and a 5-year DFS of 65 Ϯ 12%, consistent with the other reported trials. In our patients with у10 nodes the presence of hormone receptor positivity, but not primary tumor size, stage, or number of involved axillary lymph nodes, predicted a better 5-year DFS and OS. This is consistent with data reported by Somlo et al 40 where PgR positivity predicted better DFS and OS and ER positivity predicted better OS in stage II/IIIA patients with at least one involved axillary lymph node undergoing HDCT.
HDCT trials in primary breast cancer have been criticized for selection bias, the routine use of hormone agents, and the routine use of radiation therapy in mastectomized patients as variables skewing outcomes in a favorable direction. 12, 38, 41, 42 Most HDCT trials require more extensive staging procedures than conventional-dose chemotherapy Bone Marrow Transplantation trials with the intention of excluding otherwise acceptable HDCT candidates if micrometastatic disease is discovered. One small study upstaged 23% of primary breast cancer patients with у10 nodes through extensive staging. 41 The true probability of upstaging will be answered by the large Intergroup trial (CALGB 9082/SWOG 9114/NCIC MA-13) comparing HDCT to a conventional-dose chemotherapy regimen in patients with у10 nodes. 43 This study required extensive staging (including bone marrow biopsies) before study enrollment. Of note, the Milan phase II study of highdose sequential chemotherapy with PSC rescue in patients with у10 nodes did not require extensive staging. 8 The outcomes with HDCT were compared to concurrent (nonrandomized) controls staged identically but treated with conventional-dose chemotherapy. The HDCT patients in this trial had significantly better DFS and a trend toward better OS than conventionally treated patients. 8 This suggests extensive staging may play little role in the apparent benefits of HDCT for primary breast cancer.
The contribution of hormone therapy to the outcomes of HDCT in primary breast cancer is uncertain. In our study, 67% of patients with у10 nodes in whom hormone receptor status was known were hormone receptor positive. It is not surprising that these patients fared better than those who were hormone receptor negative. HDCT trials in patients with у10 nodes do not select more hormone receptor-positive patients (range, 56-67%; weighted mean, 61%) (Refs 6, 8, 40 and the current series) than conventional-dose chemotherapy trials in the same group (range, 42-74%; weighted mean, 58%). 6, 8, [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] Sixty-two percent of 479 patients undergoing HDCT and reported to the Autologous Blood and Marrow Transplant Registry (ABMTR) were ER positive. 44 Several conventional-dose chemotherapy studies in у10 nodes utilized tamoxifen after adjuvant chemotherapy with 5-year DFS of 17-56% (weighted average, 32%), 6, 7, [28] [29] [30] 35, 36, 38 results still inferior to HDCT trials utilizing tamoxifen (Refs 6, 7, 39, 40 and the current series). The Milan HDCT trial did not use tamoxifen and its results were similar to other HDCT trials which suggested that the contribution of hormone therapy to HDCT is not likely to be great. 8 Two prospective, randomized trials established that radiation therapy added to adjuvant conventional-dose chemotherapy in mastectomized primary breast cancer patients Bone Marrow Transplantation improved local-regional control, DFS and OS. 45, 46 A retrospective study showed radiation therapy added to conventional-dose adjuvant chemotherapy in mastectomized patients with у10 nodes reduced the odds of relapse by 20%. 42 Most conventional-dose adjuvant chemotherapy trials have not added radiation therapy to mastectomized patients. Since HDCT trials in patients with у10 nodes have routinely utilized radiation therapy even in mastectomized patients, one must presume that radiation therapy may contribute to improved outcomes. It is unlikely that radiation therapy is the sole reason for the observed improvements as many HDCT patients did not have mastectomies.
To date, three prospective, randomized trials with reasonable follow up (49-70 months) have been performed and reported comparing HDCT to conventional-dose chemotherapy in patients with high-risk primary breast cancer. [47] [48] [49] Two trials were small and showed no difference in DFS or OS between treatment groups. 47, 48 However, these two trials only had the statistical power to detect a relative 4-year DFS difference of greater than 30%. If the Milan trial is reflective of truth, the relative DFS difference comparing HDCT to conventional-dose chemotherapy will be less than 30%. 8 A larger trial from South Africa found that tandem mitoxantrone-based HDCT was superior to conventionaldose chemotherapy (median DFS, Ͼ7.7 vs 3.6 years, P Ͻ 0.05; and median OS, Ͼ7.7 vs 6.1 years, P Ͻ 0.05). 49 The large, randomized Intergroup trial in patients with у10 nodes currently has short follow-up but is showing a trend toward fewer relapses in the HDCT arm. 43 HDCT data on stage IIIB breast cancer are emerging. The PFS in 1344 patients receiving HDCT ranges 33-85% (weighted mean, 53%) at follow-ups ranging 14-60 months (weighted mean, 37.5 months). 40, 50 In our series, the 5-year DFS for patients undergoing HDCT was 47 Ϯ 19%. In published trials with long follow-up of IIIB patients receiving conventional-dose chemotherapy combined with surgery, radiation, and hormone therapy, the weighted average 5-year DFS was 34% (range, 10-54%). 51 It is too early to tell whether HDCT is making an impact on stage IIIB breast cancer.
At the outset our foremost interest was in using HDCT for high risk primary breast cancer, a group we felt most likely to benefit from dose intensity. As such, during the phase I development of CTM, stage IIIB/IV patients served to test mitoxantrone doses one level ahead of stage II/IIIA patients in the hope that the lower stage patients would not be subjected to dose-limiting toxicities. Therefore, we did not restrict stage IV patients to those responding to their initial induction chemotherapy as in many HDCT trials for stage IV breast cancer. Rather, we accrued a heterogeneous group of stage IV patients who received a median of two (1) (2) (3) (4) (5) different chemotherapy regimens to demonstrate responsiveness. Despite this heterogeneity, the CR rate was 47% in our patients as of the 3 month assessment after CTM. This CR rate is consistent with other HDCT trials in metastatic breast cancer (range, 6-55%; weighted average 40%) 13, 21, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] and substantially higher than CR rates seen with conventional-dose chemotherapy (range, 4-23%; weighted average 17%). 11, 13, 62, 63 The median PFS and OS in our patients (15 and 28 months, respectively) are consistent with other HDCT trials (weighted average PFS, 10 months (range, 6-20 months); weighted average OS, 19 months (range, 10-24 months)). 13, 21, [53] [54] [55] [56] [58] [59] [60] [61] Several factors have been found to be predictive of outcomes after HDCT for metastatic breast cancer: response to conventional-dose chemotherapy, prior adjuvant chemotherapy, number of metastatic organ sites involved, length of interval from diagnosis to metastasis, and sites of metastasis. 21, 44, 60, 61, 64 By univariate analysis, only response to conventional-dose chemotherapy was predictive in our patients. Achieving a CR prior to CTM predicted better 5-year OS (33 Ϯ 21%) than achieving PR (14 Ϯ 13%; P = 0.05). Antman et al 21 demonstrated that patients achieving PR ‡ prior to HDCT did as well as those achieving CR, a finding we were able to confirm (5-year PFS if in CR, 13 Ϯ 20%; if in PR ‡ , 27 Ϯ 26%). In our patients, the combined group of patients acheiving CR or PR ‡ had a better 5-year EFS (21 Ϯ 15% vs 11 Ϯ 11%; P = 0.026) and OS (40 Ϯ 17% vs 14 Ϯ 13%; P = 0.008; Figure 3 ) than patients achieving PR. The 5-year DFS of our patients entering CTM in CR/PR ‡ (21 Ϯ 16%) appears better than that reported for HDCT 'candidates' achieving CR to conventional-dose chemotherapy for metastatic breast cancer (10%). 11 The 4-year PFS and OS of our CR patients (26 Ϯ 20% and 33 Ϯ 21%) closely resembles the 4-year PFS and OS of CR patients (30 and 40%) reported to the ABMTR. 44 CTM thus appears to be a HDCT regimen as effective as other HDCT regimens reported for metastatic breast cancer. Our failure to confirm other reported prognostic factors may be the result of heterogeneity and heavily pre-treated status of our stage IV patients.
An important component of the safety and efficacy of CTM is mitoxantrone. Mitoxantrone is an anthracene derivative with activity against breast cancer but little pulmonary toxicity. 23, [65] [66] [67] [68] [69] [70] [71] Compared to doxorubicin, mitoxantrone appears to demonstrate less cardiac and gastrointestinal toxicity. 23, [70] [71] [72] We reasoned that dose escalation of mitoxantrone would be more successful than doxorubicin in the setting of hematopoietic stem cell rescue. We were able to easily escalate mitoxantrone to 60 mg/m 2 without demonstrating dose-limiting toxicity to the oral mucosa, gastrointestinal tract, lungs, skin or liver. After 91 patients were treated with CTM, however, we elected not to escalate mitoxantrone further due to the development of severe cardiac toxic events which were a function of lifetime anthracycline exposure. Six patients experienced severe cardiac events, four of whom had ⌺ Doxo Eq Ͼ400 mg/m 2 and five of whom were stage IV patients. Dose escalation of mitoxantrone beyond 60 mg/m 2 would place most of our stage IV patients above the 400 mg/m 2 threshold and put them at unreasonable risk for cardiac injury. Therefore, we chose to dose-adjust mitoxantrone. By doing so, there have been no further severe cardiac events in the last 100 patients treated with CTM. Changing mitoxantrone administration from a bolus to a 21-h infusion did not impact on LVEF determined 1 year post HDCT.
Other investigators have utilized mitoxantrone as part of HDCT for stage IV breast cancer. 13 53 we believe mitoxantrone could be safely escalated beyond 60 mg/m 2 in CTM in those patients with little prior anthracycline exposure.
We saw little pulmonary injury with CTM. High-dose thiotepa rarely causes pulmonary injury when used as a single agent. 77, 78 Mitoxantrone is not known to cause pulmonary injury. 23, 69 Cyclophosphamide and its active metabolite acrolein have both been reported to decrease hepatic reduced-glutathione levels, thus compromising the ability of pulmonary tissue to protect itself from oxidant damage. 15, 79 The combination of cyclophosphamide and thiotepa, with or without carboplatin, as HDCT for breast cancer has been associated with no significant pulmonary toxicity in 97 reported patients. 21, 54, 55, 80 In our series, two patients (1%) experienced significant pulmonary injury, both with diffuse alveolar hemorrhage syndrome (DAH). DAH can complicate any high-dose regimen, including those containing total body irradiation 24, 25, 81 and is probably not specific for CTM. We had no cases of early or late interstitial pneumonitis. This contrasts favorably with the 9-53% incidence of interstitial pneumonitis reported with the CPB regimen where carmustine and cyclophosphamide are the putative pulmonary toxins. 6, [14] [15] [16] Although CTM is safe with regards to the lungs, it is quite immunosuppressive as exemplified by seven cases (3.6%) of CMV infection and nine cases (4.7%) of Herpes zoster reactivation.
In conclusion, CTM is a safe and effective HDCT regimen for breast cancer. Cardiac toxicity is a function of prior anthracycline exposure and can be substantially reduced by mitoxantrone dose adjustment. Further, CTM has little pulmonary toxicity and no interstitial pneumonitis which complicates carmustine-based regimens. CTM produced excellent results in patients with primary breast cancer and у10 nodes. This favorable pilot study has provided Bone Marrow Transplantation the impetus to use CTM as the HDCT arm of a national German phase III study comparing HDCT to conventionaldose chemotherapy in primary breast cancer patients with у10 nodes. 82 
